Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda Pharmaceutical Co has decided to discontinue its cell therapy research as part of a strategic portfolio prioritization process. The company plans to seek an external partner to advance its cell therapy platform technologies. This decision will result in an impairment loss of approximately JPY 58.0 billion, primarily related to intangible assets associated with the gamma delta T-cell therapy platform. Takeda will redirect its investments towards programs that promise transformative therapies, focusing on small molecules, biologics, and antibody-drug conjugates.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading R&D-driven biopharmaceutical company headquartered in Japan. It focuses on creating transformative treatments in areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With a commitment to patients, the company operates in approximately 80 countries and regions.
Average Trading Volume: 4,652,522
Technical Sentiment Signal: Buy
Current Market Cap: Yen6783.7B
See more insights into 4502 stock on TipRanks’ Stock Analysis page.